Actively Recruiting
Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma
Led by University of California, San Francisco · Updated on 2025-12-12
250
Participants Needed
1
Research Sites
272 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
H
Haystack Oncology, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a single-center, non-interventional, observational study that evaluates the correlation of circulating tumor DNA (ctDNA) testing to cancer relapse for participants with squamous cell carcinomas (HNC) of the head and neck mucosa and skin after curative-intent primary radiation or surgery.
CONDITIONS
Official Title
Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have confirmed squamous cell carcinoma of the head and neck mucosa or skin.
- Participants must be 18 years of age or older.
- Participants must be planning to receive curative-intent surgery or radiation treatment as part of standard care.
- Participants must be able to understand and willing to sign a written informed consent form.
You will not qualify if you...
- Participants with any contraindication to giving 20 mL of blood at each time point (up to 300 mL total over 15 collections) are excluded.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
S
Sonia Contreras Martinez
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here